openPR Logo
Press release

Revenue Growth of the HER2-Positive Breast Cancer Market to be Influenced by Growing End-use Adoption 2023-2031

12-27-2023 07:08 PM CET | Health & Medicine

Press release from: Global Insight Services

Revenue Growth of the HER2-Positive Breast Cancer Market to be

The HER2-Positive Breast Cancer Market is a crucial segment of the broader oncology pharmaceutical industry, focused on addressing a specific type of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer is an aggressive subtype, accounting for about 20-25% of all breast cancer cases. The market for HER2-positive breast cancer treatments has witnessed significant advancements in recent years, primarily driven by the development of targeted therapies like Herceptin (trastuzumab) and other monoclonal antibodies, as well as small molecule inhibitors such as lapatinib and pertuzumab. These therapies have revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and reducing the risk of recurrence.

Request for Free Sample @ https://www.globalinsightservices.com/request-sample/GIS26121/?utm_source=sidram&utm_medium=openpr&utm_campaign=27122023

As the understanding of HER2-positive breast cancer's molecular underpinnings continues to evolve, the market is poised for further growth. The introduction of novel therapies, combination regimens, and immunotherapies, as well as the ongoing efforts to identify potential biomarkers and patient-specific treatment approaches, are expected to shape the market's future. Additionally, the growing prevalence of breast cancer worldwide and the increased awareness about the importance of early detection are likely to drive market expansion. Despite the remarkable progress in HER2-positive breast cancer treatment, research and innovation remain critical to improving patient outcomes and reducing the overall burden of this aggressive cancer subtype.

Key Trends

Key trends in the HER2-Positive Breast Cancer Market include the ongoing development of innovative targeted therapies and immunotherapies that aim to enhance treatment efficacy and reduce side effects, as well as the exploration of combination treatment strategies to address resistance and improve long-term outcomes for patients. Furthermore, there is a growing emphasis on precision medicine, with efforts to identify specific biomarkers and subtypes within HER2-positive breast cancer that can guide more personalized treatment decisions. Another notable trend is the increasing use of real-world data and artificial intelligence for clinical research, enabling better understanding of treatment responses and long-term patient outcomes.

Read Full Research Report @ https://www.globalinsightservices.com/reports/her2-positive-breast-cancer-market//?utm_source=sidram&utm_medium=openpr&utm_campaign=27122023

Key Drivers

Several key drivers fuel the HER2-Positive Breast Cancer Market's growth and development. Firstly, the rising incidence of breast cancer, along with the increasing recognition of HER2-positive breast cancer subtypes, is expanding the patient pool in need of targeted therapies, driving market demand. The continued evolution of precision medicine and molecular diagnostics is enabling more accurate identification of HER2-positive patients, leading to tailored treatment approaches and improved patient outcomes. Additionally, ongoing research and development efforts are resulting in the approval of novel therapies and combination regimens, providing healthcare providers with a wider range of options to manage the disease.

Buy Now@ https://www.globalinsightservices.com/checkout/single_user/GIS26121/?utm_source=sidram&utm_medium=openpr&utm_campaign=27122023

Market Segmentation : HER2-Positive Breast Cancer Market

HER2-Positive Breast Cancer Market By Treatment Type : Chemotherapy, Targeted Therapy, Immunotherapy, Others

HER2-Positive Breast Cancer Market By Route of Administration : Oral, Parenteral, Others

HER2-Positive Breast Cancer Market By End-Users : Hospitals, Homecare, Specialty Centres, Others

HER2-Positive Breast Cancer Market By Region : North America : US, Canada, Mexico, Europe : The UK, Germany, France, Italy, Spain, Netherlands, Switzerland, Asia-Pacific : China, India, Japan, South Korea, Australia, Singapore, Indonesia, Rest of Asia-Pacific, Rest of the World : Latin America, Middle East, Africa

Key Players

Johnson & Johnson Private Limited (U.S.)
Cipla Inc. (U.S.)
Abbott (U.S.)
AbbVie Inc. (U.S.)
Merck KGaA (Germany)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India
Lupin (India)
Hikma Pharmaceuticals PLC (U.K.)
Amneal Pharmaceuticals LLC. (U.S.)
Pfizer Inc (U.S.)

Request for Customization @ https://www.globalinsightservices.com/checkout/single_user/GIS26121/?utm_source=sidram&utm_medium=openpr&utm_campaign=27122023

With Global Insight Services, you receive :

10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology

About Global Insight Services :

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us :

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 15998
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Revenue Growth of the HER2-Positive Breast Cancer Market to be Influenced by Growing End-use Adoption 2023-2031 here

News-ID: 3339228 • Views:

More Releases from Global Insight Services

Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing at 17.5% CAGR | Overall Study Report
Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing …
The Immuno Oncology Drugs Market is rapidly emerging as a transformative segment in the global healthcare industry. These drugs harness the body's immune system to identify and attack cancer cells, offering innovative treatment alternatives to traditional chemotherapy and radiation therapies. Immuno-oncology therapies include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T cells. The growth of this market is primarily driven by advancements in biotechnology, an improved
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Overall Study Report
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Ove …
The GLP 1 Market is experiencing unprecedented growth, fueled by the rising prevalence of type 2 diabetes and obesity globally. GLP-1, or glucagon-like peptide-1 receptor agonists, represents a groundbreaking therapeutic class that improves insulin secretion, reduces glucagon production, and slows gastric emptying. These mechanisms not only enhance glycemic control but also support weight management, making GLP-1 therapies a preferred choice among healthcare providers and patients alike. Over the years, the
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAGR | Key Players: EasyMile, Navya, Aurrigo
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAG …
Market Overview Autonomous Bus Market is revolutionizing the future of urban mobility through advanced automation technologies. Valued at $2.1 billion in 2024, the market is projected to reach $11.6 billion by 2034, expanding at a strong CAGR of 18.8%. This market focuses on the development and deployment of self-driving buses equipped with cutting-edge sensors, artificial intelligence, and vehicle-to-everything (V2X) communication systems. These buses are designed to improve road safety, enhance passenger
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | Key Players: Apollo Tyres, Nokian Tyres, Hankook Tire
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | …
Market Overview Automotive Tire Market is experiencing remarkable growth as the industry embraces innovation, sustainability, and digital transformation. Valued at $406 billion in 2024, the market is projected to soar to $976.7 billion by 2034, reflecting a CAGR of 9.2%. This expansion is primarily driven by the surge in global vehicle production, growing consumer preference for durable and high-performance tires, and the increasing adoption of smart tire technologies. The Automotive Tire

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain. Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report: • DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with